vTv Therapeutics (NASDAQ:VTVT) Earns “Buy” Rating from BTIG Research

vTv Therapeutics (NASDAQ:VTVT)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $57.00 price target on the biotechnology company’s stock. BTIG Research’s target price indicates a potential upside of 102.47% from the stock’s previous close.

Several other research firms have also recently issued reports on VTVT. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective for the company. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Performance

VTVT stock traded down $0.08 during trading on Wednesday, reaching $28.15. 7,457 shares of the company were exchanged, compared to its average volume of 53,452. vTv Therapeutics has a 52-week low of $19.50 and a 52-week high of $44.00. The stock’s 50 day moving average price is $31.90 and its 200 day moving average price is $33.55. The company has a market cap of $110.92 million, a P/E ratio of -26.56 and a beta of 0.21.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, equities research analysts forecast that vTv Therapeutics will post -2.35 EPS for the current year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.